Lofexidine is an alpha-2-A noradrenergic receptor agonist approved in the United Kingdom for treating opioid withdrawal symptoms. Due to relatively poor detox success rates locally, we introduced a novel regime – the BristoL (Buprenorphine-Lofexidine) protocol (table 1):

We assessed the efficacy of this regime in our outpatients (annual numbers coming into treatment 120-150/year) compared to previous client-led regimes.

Retrospective case notes review and electronic patient management software were used to calculate changes in opiate-free exits.

Drug free exits in the first year after introducing the BristoL protocol dramatically increased by 140% (from 5 to 12) and doubled again the following year (29) with comparable figures the year after (26) demonstrating a sustained effect (figure 1).

Introducing the BristoL protocol led to a dramatic improvement in opiate-free exits over three years with good tolerability and no significant side effects. Its advantages – simplified prescribing, reduced monitoring and a dramatically improved reported patient experience – have meant we are now also using it in the primary care setting.